Vaxart, Inc. – NASDAQ:VXRT
Vaxart stock price today
$0.355
-0.37
-51.42%
Financial Health
0
1
2
3
4
5
6
7
8
9
Market closed
Open in about 14 hours
Vaxart stock price monthly change
+9.06%
month
Vaxart stock price quarterly change
+9.06%
quarter
Vaxart stock price yearly change
+21.83%
year
Vaxart key metrics
Market Cap | 133.48M |
Enterprise value | 53.43M |
P/E | -0.73 |
EV/Sales | 278.32 |
EV/EBITDA | -0.35 |
Price/Sales | 404.93 |
Price/Book | 0.70 |
PEG ratio | 0.01 |
EPS | -0.52 |
Revenue | 7.23M |
EBITDA | -73.93M |
Income | -81.74M |
Revenue Q/Q | 223.11% |
Revenue Y/Y | 937.30% |
Profit margin | -84525.52% |
Oper. margin | -28136.98% |
Gross margin | 0% |
EBIT margin | -28136.98% |
EBITDA margin | -1022.61% |
Sign up &
create your own Smart Feed
create your own Smart Feed
Personalize your watchlist with companies you want to keep track of and get notified in the smart feed every time fresh news arrives.
Sign up for freeVaxart stock price history
Vaxart stock forecast
Vaxart financial statements
| Jun 2023 | 1.35M | -22.55M | -1660.53% |
|---|---|---|---|
| Sep 2023 | 446K | -17.4M | -3901.35% |
| Dec 2023 | 3.24M | -17.37M | -535.44% |
| Mar 2024 | 2.18M | -24.41M | -1119.53% |
| Dec 2023 | 3.24M | -17.37M | -535.44% |
|---|---|---|---|
| Mar 2024 | 2.18M | -24.41M | -1119.53% |
| Oct 2025 | 200K | -20.25M | -10128.67% |
| Dec 2025 | 400K | -20.25M | -5064.33% |
Analysts Price target
Financials & Ratios estimates
| Jun 2023 | 122653000 | 37.58M | 30.64% |
|---|---|---|---|
| Sep 2023 | 105642000 | 34.12M | 32.3% |
| Dec 2023 | 91830000 | 34.02M | 37.05% |
| Mar 2024 | 88670000 | 32.97M | 37.19% |
| Jun 2023 | -17.47M | -1.58M | 13.89M |
|---|---|---|---|
| Sep 2023 | -15.00M | 4.97M | -8K |
| Dec 2023 | -13.52M | 15.10M | -66K |
| Mar 2024 | -21.19M | -5.02M | 18.19M |
Vaxart alternative data
| Aug 2023 | 164 |
|---|---|
| Sep 2023 | 164 |
| Oct 2023 | 164 |
| Nov 2023 | 164 |
| Dec 2023 | 164 |
| Jan 2024 | 164 |
| Feb 2024 | 164 |
| Mar 2024 | 109 |
| Apr 2024 | 109 |
| May 2024 | 109 |
| Jun 2024 | 109 |
| Jul 2024 | 109 |
Vaxart other data
100.00%
0.00%
of VXRT is owned by hedge funds
69
-54
12.73M
-31.58M
shares is hold by hedge funds
What is insider trading?
| Period | Buy | Sel |
|---|---|---|
| Jun 2024 | 20000 | 0 |
| Transaction | Date | Insider | Security | Shares | Price per share | Total value | Source |
|---|---|---|---|---|---|---|---|
Purchase | WATSON W. MARK director | Common Stock | 20,000 | $0.68 | $13,580 | ||
Purchase | WATSON W. MARK director | Common Stock | 20,000 | $0.76 | $15,140 | ||
Option | YEDID ROBERT A. director | Common Stock | 8,000 | $2.39 | $19,120 | ||
Option | YEDID ROBERT A. director | Common Stock | 18,240 | $0.31 | $5,654 | ||
Option | YEDID ROBERT A. director | Stock Option (right to buy) | 8,000 | $2.39 | $19,120 | ||
Option | YEDID ROBERT A. director | Stock Option (right to buy) | 18,240 | $0.31 | $5,654 | ||
Purchase | AHMAD FUAD officer: Interim .. | Common Stock | 5,000 | $3.22 | $16,100 | ||
Option | TUCKER SEAN officer: SVP, Chi.. | Stock Option (right to buy) | 40,000 | $0.77 | $30,800 | ||
Option | TUCKER SEAN officer: SVP, Chi.. | Common Stock | 40,000 | $0.77 | $30,800 | ||
Option | ECHERD MARGARET officer: SVP, Pri.. | Stock Option (right to buy) | 666 | $5.17 | $3,443 |
| Quarter | Transcript |
|---|---|
| Q1 2024 13 May 2024 | Q1 2024 Earnings Call Transcript |
| Q4 2023 14 Mar 2024 | Q4 2023 Earnings Call Transcript |
| Q3 2023 2 Nov 2023 | Q3 2023 Earnings Call Transcript |
| Q2 2023 3 Aug 2023 | Q2 2023 Earnings Call Transcript |
| Insider | Compensation |
|---|---|
Mr. Cezar Andrei Floroiu M.B.A. (1973) Chief Executive Officer, Pres, Principal Financial Officer & Director | $538,150 |
| Dr. Sean N. Tucker (1968) Senior Vice President & Chief Scientific Officer | $530,720 |
| Ms. Margaret A. Echerd (1959) Senior Vice President & Principal Accounting Officer | $523,070 |
Vaxart: A Speculative Biotech With Potential As Covid-19 Play And Oral Vaccine Platform
Vaxart: Investment Case For An Oral COVID Vaccine Not So Hard To Swallow
Vaxart: Differentiated Covid Oral Route Remains Viable
Vaxart: World's First Oral COVID Vaccine In Development
Vaxart Has A More Sound Reason To Buy Into Its COVID-19 Vaccine Candidate
-
What's the price of Vaxart stock today?
One share of Vaxart stock can currently be purchased for approximately $0.36.
-
When is Vaxart's next earnings date?
Unfortunately, Vaxart's (VXRT) next earnings date is currently unknown.
-
Does Vaxart pay dividends?
No, Vaxart does not pay dividends.
-
How much money does Vaxart make?
Vaxart has a market capitalization of 133.48M and it's past years’ income statements indicate that its last revenue has increased compared to the previous period by 6796.26% to 7.38M US dollars.
-
What is Vaxart's stock symbol?
Vaxart, Inc. is traded on the NASDAQ under the ticker symbol "VXRT".
-
What is Vaxart's primary industry?
Company operates in the Healthcare sector and Biotechnology industry.
-
How do i buy shares of Vaxart?
Shares of Vaxart can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.
-
Who are Vaxart's key executives?
Vaxart's management team includes the following people:
- Mr. Cezar Andrei Floroiu M.B.A. Chief Executive Officer, Pres, Principal Financial Officer & Director(age: 52, pay: $538,150)
- Dr. Sean N. Tucker Senior Vice President & Chief Scientific Officer(age: 57, pay: $530,720)
- Ms. Margaret A. Echerd Senior Vice President & Principal Accounting Officer(age: 66, pay: $523,070)
-
How many employees does Vaxart have?
As Jul 2024, Vaxart employs 109 workers.
-
When Vaxart went public?
Vaxart, Inc. is publicly traded company for more then 43 years since IPO on 11 Dec 1981.
-
What is Vaxart's official website?
The official website for Vaxart is vaxart.com.
-
Where are Vaxart's headquarters?
Vaxart is headquartered at 170 Harbor Way, South San Francisco, CA.
-
How can i contact Vaxart?
Vaxart's mailing address is 170 Harbor Way, South San Francisco, CA and company can be reached via phone at +65 05503500.
Vaxart company profile:
Vaxart, Inc.
vaxart.comExchange:
NASDAQ
Full time employees:
109
Industry:
Biotechnology
Sector:
Healthcare
Vaxart, Inc., a clinical-stage biotechnology company, engages in the discovery and development of oral recombinant protein vaccines based on its proprietary oral vaccine platform. The company's product pipeline includes norovirus vaccine, an oral tablet vaccine, which is in a Phase Ib clinical trial with bivalent oral tablet vaccine for the GI.1 and GII.4 norovirus strains; seasonal influenza vaccine, which is in Phase II clinical trial for the treatment of H1 influenza infection; respiratory syncytial virus vaccine; and coronavirus vaccine, which is in Phase II clinical trial for the treatment of SARS-CoV-2 infection. It is also developing therapeutic vaccines for cervical cancer and dysplasia caused by human papillomavirus. The company is headquartered in South San Francisco, California.
170 Harbor Way
South San Francisco, CA 94080
South San Francisco, CA 94080
CIK: 0000072444
ISIN: US92243A2006
CUSIP: 92243A200
